Avadel Pharmaceuticals plc (AVDL) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
AVDL Revenue Growth
Revenue Breakdown (FY 2024)
AVDL's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
By Geography
AVDL Revenue Analysis (2013–2024)
As of May 8, 2026, Avadel Pharmaceuticals plc (AVDL) generated trailing twelve-month (TTM) revenue of $248.5 million, reflecting explosive growth of +54.9% year-over-year. The most recent quarter (Q3 2025) recorded $77.5 million in revenue, up 13.7% sequentially.
Looking at the longer-term picture, AVDL's 5-year compound annual growth rate (CAGR) stands at +23.4%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $173.2 million in 2015.
Revenue diversification analysis shows AVDL's business is primarily driven by Reportable Segment (100%). With over half of revenue concentrated in Reportable Segment, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including JAZZ (+9.2% YoY), AXSM (+63.9% YoY), and INVA (+13.6% YoY), AVDL has underperformed the peer group in terms of revenue growth. Compare AVDL vs JAZZ →
AVDL Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| AVDLCurrent | $249M | +54.9% | +23.4% | -25.1% | |
 JAZZ | $4.3B | +9.2% | +12.5% | 5.3% | |
 AXSM | $638M | +63.9% | - | -26.5% | |
 INVA | $425M | +13.6% | +4.8% | 38.5% | |
 SUPN | $719M | +16.3% | +6.7% | -5.1% | |
 PGNY | $1.3B | +6.6% | +30.2% | 6.6% |
AVDL Historical Revenue Data (2013–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $169.1M | +504.8% | $153.8M | 91.0% | $-42,399,000 | -25.1% |
| 2023 | $28.0M | - | $27.1M | 97.0% | $-137,849,000 | -493.0% |
| 2022 | $0 | - | $0 | - | $-98,561,000 | - |
| 2021 | $0 | -100.0% | $0 | - | $-85,546,000 | - |
| 2020 | $22.3M | -62.3% | $16.6M | 74.3% | $5.8M | 26.0% |
| 2019 | $59.2M | -42.7% | $47.1M | 79.5% | $-24,112,000 | -40.7% |
| 2018 | $103.3M | -40.2% | $85.8M | 83.0% | $-104,926,000 | -101.6% |
| 2017 | $172.7M | +15.0% | $156.4M | 90.6% | $88.3M | 51.1% |
| 2016 | $150.2M | -13.3% | $137.0M | 91.2% | $-4,965,000 | -3.3% |
| 2015 | $173.2M | +1072.3% | $162.3M | 93.7% | $71.4M | 41.2% |
See AVDL's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs AVDL Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare AVDL vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonAVDL — Frequently Asked Questions
Quick answers to the most common questions about buying AVDL stock.
Is AVDL's revenue growth accelerating or slowing?
AVDL revenue is accelerating at +54.9% year-over-year, exceeding the 5-year CAGR of +23.4%. TTM revenue reached $249M. Growth momentum has increased versus prior periods.
What is AVDL's long-term revenue growth rate?
Avadel Pharmaceuticals plc's 5-year revenue CAGR of +23.4% reflects the sustained expansion pattern. Current YoY growth of +54.9% is above this long-term average.
How is AVDL's revenue distributed by segment?
AVDL reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.